

Alexander J Muller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1367332/publications.pdf>

Version: 2024-02-01

63
papers

7,700
citations

101384

36
h-index

138251

58
g-index

66
all docs

66
docs citations

66
times ranked

8252
citing authors

#	ARTICLE	IF	CITATIONS
1	The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. <i>Journal of Immunology</i> , 2022, 208, 571-581.	0.4	13
2	IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFN γ /IL6 Balance to Promote Neovascularization. <i>Cancer Immunology Research</i> , 2021, 9, 514-528.	1.6	16
3	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 789473.	2.2	2
4	Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 ⁺ and CD4 ⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. , 2020, 8, e000605.		34
5	Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 1861.	2.2	70
6	Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. <i>Seminars in Immunopathology</i> , 2019, 41, 41-48.	2.8	198
7	Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 455-464.	2.6	37
8	Host <i>IDO2</i> Gene Status Influences Tumor Progression and Radiotherapy Response in <i>KRAS</i> -Driven Sporadic Pancreatic Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 724-734.	3.2	48
9	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. <i>Journal of the American College of Surgeons</i> , 2018, 226, 596-603.	0.2	5
10	Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive "Cold" Tumors "Hot". <i>Trends in Cancer</i> , 2018, 4, 38-58.	3.8	130
11	IDO/TDO Inhibition in Cancer. , 2018, , 289-307.		1
12	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 175-203.	1.6	204
13	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 370.	1.3	91
14	The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. <i>Cancer Research</i> , 2017, 77, 1783-1812.	0.4	270
15	Discovery of IDO1 Inhibitors: From Bench to Bedside. <i>Cancer Research</i> , 2017, 77, 6795-6811.	0.4	433
16	IDO1 is an Integral Mediator of Inflammatory Neovascularization. <i>EBioMedicine</i> , 2016, 14, 74-82.	2.7	75
17	IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. <i>Journal of Immunology</i> , 2016, 196, 4487-4497.	0.4	56
18	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 564-576.	2.6	33

#	ARTICLE	IF	CITATIONS
19	Cardiac-specific Disruption of Bin1 in Mice Enables a Model of Stress- and Age-Associated Dilated Cardiomyopathy. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 2541-2551.	1.2	27
20	1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. <i>Autoimmunity</i> , 2014, 47, 409-418.	1.2	18
21	IDO2 in Immunomodulation and Autoimmune Disease. <i>Frontiers in Immunology</i> , 2014, 5, 585.	2.2	112
22	IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. <i>International Immunology</i> , 2014, 26, 357-367.	1.8	168
23	IDO in Inflammatory Programming and Immune Suppression in Cancer. , 2014, , 311-346.		2
24	Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 721-735.	2.0	423
25	IDO in Immune Escape. , 2013, , 565-581.		1
26	The Tumor-Selective Cytotoxic Agent \hat{I}^2 -Lapachone is a Potent Inhibitor of IDO1. <i>International Journal of Tryptophan Research</i> , 2013, 6, IJTR.S12094.	1.0	26
27	IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. <i>Cancer Discovery</i> , 2012, 2, 722-735.	7.7	280
28	Bin1 Attenuation Suppresses Experimental Colitis by Enforcing Intestinal Barrier Function. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1813-1821.	1.1	15
29	Indoleamine 2,3-Dioxygenase Amino Acid Metabolism and Tumour-Associated Macrophages: Regulation in Cancer-Associated Inflammation and Immune Escape. , 2011, , 91-104.		0
30	Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. <i>Cancer Biology and Therapy</i> , 2011, 12, 1050-1058.	1.5	45
31	Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1655-1663.	2.0	57
32	Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1864-1871.	1.9	27
33	Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. <i>Immunotherapy</i> , 2010, 2, 293-297.	1.0	28
34	Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate. <i>Cancer Research</i> , 2010, 70, 1845-1853.	0.4	65
35	Towards a Genetic Definition of Cancer-Associated Inflammation. <i>American Journal of Pathology</i> , 2010, 176, 2082-2087.	1.9	71
36	The Immunoregulatory Enzyme IDO Paradoxically Drives B Cell-Mediated Autoimmunity. <i>Journal of Immunology</i> , 2009, 182, 7509-7517.	0.4	111

#	ARTICLE	IF	CITATIONS
37	IDO recruits Tregs in melanoma. <i>Cell Cycle</i> , 2009, 8, 1818-1822.	1.3	27
38	BAR the door: Cancer suppression by amphiphysin-like genes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1795, 25-36.	3.3	47
39	Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target. <i>Journal of the American College of Surgeons</i> , 2009, 208, 781-787.	0.2	118
40	Immune Escape: Role of Indoleamine 2,3-Dioxygenase in Tumor Tolerance. , 2009, , 257-283.		1
41	Indoleamine 2,3-dioxygenase in T cell tolerance and tumoral immune escape. <i>Immunological Reviews</i> , 2008, 222, 206-221.	2.8	368
42	Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4968-4977.	2.9	148
43	Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1706-1718.	2.9	151
44	Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17073-17078.	3.3	214
45	<i>Bin3</i> Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. <i>Cancer Research</i> , 2008, 68, 1683-1690.	0.4	27
46	Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 31-40.	0.8	125
47	Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. <i>Cancer Research</i> , 2007, 67, 792-801.	0.4	557
48	<i>Bin1</i> Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression. <i>Cancer Research</i> , 2007, 67, 100-107.	0.4	35
49	Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound <i>d</i> -1-Methyl-Tryptophan. <i>Cancer Research</i> , 2007, 67, 7082-7087.	0.4	453
50	<i>Bin1</i> Ablation Increases Susceptibility to Cancer during Aging, Particularly Lung Cancer. <i>Cancer Research</i> , 2007, 67, 7605-7612.	0.4	59
51	Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan. <i>International Congress Series</i> , 2007, 1304, 250-261.	0.2	1
52	Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition. , 2007, , 347-368.		0
53	Structure-Activity Study of Brassinin Derivatives as Indoleamine 2,3-Dioxygenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 684-692.	2.9	161
54	Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. <i>Nature Reviews Cancer</i> , 2006, 6, 613-625.	12.8	239

#	ARTICLE	IF	CITATIONS
55	Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. <i>Nature Medicine</i> , 2005, 11, 312-319.	15.2	998
56	Marrying Immunotherapy with Chemotherapy: Why Say IDO?: Figure 1.. <i>Cancer Research</i> , 2005, 65, 8065-8068.	0.4	105
57	Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 831-849.	1.5	100
58	Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. <i>Cancer Biology and Therapy</i> , 2004, 3, 1236-1242.	1.5	23
59	Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. <i>Oncogene</i> , 2003, 22, 3578-3588.	2.6	21
60	Targeted Disruption of the Murine Bin1/Amphiphysin II Gene Does Not Disable Endocytosis but Results in Embryonic Cardiomyopathy with Aberrant Myofibril Formation. <i>Molecular and Cellular Biology</i> , 2003, 23, 4295-4306.	1.1	118
61	Genetic mapping of the embryonal carcinoma transplantation resistance locus Gt(B6) to mouse Chromosome 8. <i>Immunogenetics</i> , 1999, 49, 949-956.	1.2	1
62	The gas5 gene is disrupted by a frameshift mutation within its longest open reading frame in several inbred mouse strains and maps to murine Chromosome 1. <i>Mammalian Genome</i> , 1998, 9, 773-774.	1.0	36
63	BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. <i>Cell</i> , 1991, 66, 161-171.	13.5	362